Company Overview
Evaxion A/S operates as a clinical-stage biotechnology company focused on the development of artificial intelligence-powered immunology vaccines designed to treat advanced melanoma and solid tumors. The firm develops specific assets such as EVX-01, which is currently undergoing a phase 2 global multi-center clinical trial for advanced melanoma, and EVX-03, a DNA-based cancer vaccine targeting solid tumors. This entity functions within the healthcare sector, specifically the biotechnology industry, where its primary objective is advancing medical treatments through proprietary vaccine technologies rather than traditional pharmaceutical sales. The company's current market capitalization stands at $29.36M, supported by an annual revenue of $7.53M and a workforce of 46 employees. These financial figures indicate that Evaxion A/S is a small-cap entity with a limited revenue base relative to its valuation, suggesting a high reliance on future clinical trial outcomes and intellectual property appreciation to justify its current market worth rather than established commercial cash flows.
Financial Health
The company reported a revenue of $7.53M over the trailing twelve months, yet generated a net income of $-7,707,000 and an EBITDA of $-8,873,000. The significant gap between the positive revenue figure and the substantial negative net income reveals a cost structure where operating expenses, likely driven by research and development for clinical trials, far exceed the revenue generated by early-stage product candidates. Free cash flow stands at $-4,449,750, which indicates that the company is consuming cash reserves to fund its operations and development pipeline, thereby limiting immediate financial flexibility for expansion or large-scale acquisitions. Regarding profitability margins, the gross margin is recorded at 100.0%, suggesting that revenue is recognized before the deduction of cost of goods sold, typical for early-stage biotech, while the operating margin is -122.7% and the profit margin is -102.4%, both reflecting heavy investment in R&D that suppresses current profitability. The balance sheet shows cash holdings of $23.23M against total debt of $7.50M, resulting in a debt-to-equity ratio of 44.04, which suggests a leveraged position given the negative equity context, though the absolute debt level is manageable relative to cash on hand. Liquidity is robust with a current ratio of 5.85, indicating that the company holds significantly more current assets than current liabilities and can comfortably meet short-term obligations. Finally, the return on equity is -100.2% and the return on assets is -28.2%, metrics that reveal management is currently destroying value on a per-share and per-asset basis due to the lack of profitable operations at this stage of development.
Valuation Assessment
Valuation metrics for Evaxion A/S show a trailing P/E ratio that is N/A due to negative earnings, while the forward P/E is listed at 88.00, implying that the market is pricing in significant future earnings growth that has not yet been realized. The price-to-book ratio is 1.72, indicating that the market values the company at a premium of 72% over its tangible book value, a common valuation multiple for biotech firms with high-potential intellectual property assets. Alternative valuation metrics include a price-to-sales ratio of 3.90 and an EV/EBITDA of -163.66, which suggests the company is valued based on revenue generation rather than profitability or earnings power, typical for pre-revenue or cash-burning companies. The stock's trading range over the last year has oscillated between a 52-week high of $12.15 and a 52-week low of $1.20, providing a wide band of volatility within which the current price must be situated. The beta value is 0.32, which indicates that the stock price exhibits low volatility relative to the broader market and is less sensitive to general market fluctuations.
Growth & Income
Revenue growth year-over-year is -100.0%, while earnings growth is N/A, indicating that the company is not currently expanding its top line and has no historical earnings growth to analyze. The negative revenue growth rate implies a contraction in sales, which is characteristic of a company that may have recently spun off revenue or is in a transition phase before commercialization begins. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning that all available earnings, had they been positive, would be reinvested into growth rather than distributed to shareholders. Consequently, the overall growth and income profile is defined by a total lack of income generation through dividends and a negative revenue trajectory that relies entirely on the successful advancement of its clinical pipeline to reverse.